For patients who meet criteria to be treated with 3 months of CAPEOX based on IDEA study, is it reasonable to use capecitabine alone for 3 months and drop oxaliplatin during the COVID pandemic?
Given that majority of benefit is derived from the capecitabine, would this be an acceptable option to decrease patient contact with the healthcare system? Would you increase duration to 6 months if using the single agent?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey
Answered on
This is indeed a question for our times. There are no data to support three months of capecitabine. In fact, the studies that suggest the single agent fluoropyrimidine carries more of the benefit than oxaliplatin are all based on six-month trials.
While single agent capecitabine may be necessary if...
Join for free or sign in to see the full answer